We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Regulations and guidance on combination products continue to evolve both domestically and abroad. As the regulatory guidance and expectations around drug-device combination products continues to develop, the topic of Essential Performance Requirements (EPRs) has been applied to drug-device combination products in the United States market. EPRs should be chosen based on a risk-based process and documented to show they are appropriate for the specific combination product application. This includes addressing risk-based scientific and technological considerations of the combination product system. Understanding how to identify EPRs as well as determining the analytical approach and control strategies for EPRs is critical to the development of a combination product. Extractables and leachables analysis of the materials in devices and primary containment systems for combination products is also a key factor and needs to be part of the testing strategy.
Essential Performance Requirements are critical design input requirements that are essential to the safe and effective operation and use of a combination product. The requirements that are achieved should be at an acceptable level of risk and determined by design specification risk assessment. EPRs are usually a subset of Critical Quality Attributes (CQAs) in Drug Quality by Design (QbD) language. These are normally addressed in stability and then tested upon release once approved.
EPR identification is addressed during risk assessment of the combination product. There are several tools that can be used for risk assessment including but not limited to:
During the risk assessment, you would identify the risks and develop action plans to clarify EPR risks and you will also develop risk reduction plans and link EPR controls to those plans. Once the EPR controls are identified, you will need to determine your testing strategy for those controls. A good place to start are the appropriate ISO standards and normative references. You can start by mapping the appropriate standards for your product such as ISO 11040 Series for Prefilled Syringes. An example of this mapping is below in Figure 1:
Figure 1
Based on the mapping, you are able to determine the appropriate performance tests to assess the EPRs. In Figure 2 below, these are some common CQA and EPR performance tests for a Prefillable Syringe System:
Figure 2
It is anticipated that an EPR Guidance by the FDA will be published by the end of 2023 which will provide further clarification for those manufacturers that are producing combination products.
Another aspect of testing that is important to address for combination products is extractables and leachables. As combination products have become more complex and regulatory requirements have been continuously changing, it is important to understand how to perform extractables and leachables testing for combination products. In combination products, you may have two different approaches that you may need to take depending on the type of product. For example, you may need to test the primary containment system by the USP <1663> Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems, USP <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems and the PQRI Guidance Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular), however, for the device such as the autoinjector, you will want to approach the testing by following ISO 10993 requirements, specifically ISO 10993-1, 17, 18. Figure 3 below outlines both of these approaches:
Figure 3
In conclusion, it is important to address these early in combination product development and to have an appropriate testing strategy in place to address EPR identification and testing as well as an appropriate extractables and leachables approach.
Click here to check out our regulatory insights on EPRs.
Learn how West is supporting customers on their combination product journey here.
The FDA states: <em>Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality or purity of the drug beyond the official or established requirements.* </em>While they make this statement, there is no prescription offered in actually how to execute an extractables and leachables evaluation, which is, of course, an essential aspect of demonstrating suitability of containers and closures.
Demonstrating the compatibility of any material in contact with drug product throughout its lifecycle (manufacture, containment, and delivery) is a necessity for a regulatory submission. Defined as extractables and leachables, these assessments continue to evolve and expand due to consistently increasing regulatory agency expectations. Agency expectations require you to act sooner rather than later. Waiting until Phase III in drug development can lead to delays and additional costs due to poor assessments that are questioned by the reviewer, or incomplete submissions that require you to redo or execute additional work. You can start your Extractables and Leachables (E&L) assessment as soon as you have selected your packaging components.
Combination products open up new vistas when it comes to delivering innovative therapies to patients in need, but teams bringing these products to the market face a number of significant hurdles. Recent surveys conducted by West at workshops held in PA and AZ revealed some of our customers’ biggest challenges. This is the final of our three blogs focused on these challenges — and how West can help Simplify the Journey™ when it comes to developing a combination product.
The combination product market has seen a significant amount of growth,<sup>i</sup> driven primarily by the rise in chronic disease indications, the demands for self-administered therapies and technological advancements. The use of combination products simplifies the process of drug administration for the patient and/or the caregiver and, in some cases, allows the patient to receive treatment at home rather than having to travel to a medical facility. However, there are many challenges that need to be navigated as one considers the transition from a vial system to a needle-based combination product.
The concept of Extractables and Leachables (E&L) is well known today, especially since the publication of United States Pharmacopeia (USP) monographs <1663><sup>1</sup> and <1664><sup>2</sup>. USP <1663> defined extractables as “organic and inorganic chemical entities that are released from a pharmaceutical packaging/delivery system and into an extraction solvent under laboratory conditions.” Leachables are defined in USP <1664> as “foreign organic and inorganic chemical entities that are present in a packaged drug product because they have migrated into the packaged drug product from a packaging/delivery system, packaging component or packaging material of construction under normal conditions of storage and use or during drug product stability studies.”
English
Chinese
